Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis
Yıl: 2021 Cilt: 38 Sayı: 1 Sayfa Aralığı: 7 - 12 Metin Dili: İngilizce DOI: 10.5152/balkanmedj.2021.20121 İndeks Tarihi: 15-05-2021
Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis
Öz: Background: Bevacizumab-combined chemotherapy is a new regimen for advanced/recurrent endometrial cancer.Aims: To evaluate the efficacy and safety of bevacizumab-combined chemotherapy in advanced/recurrent endometrial cancer.Study design: Systematic review and meta-analysis.Methods: Eligible studies were retrieved from Embase, PubMed, and Cochrane Library. The data of primary outcomes including progression-free survival and overall survival and secondary outcomes including overall survival, response rate, and adverse events (grade ≥2) were extracted, pooled, and used for the meta-analysis to compare the efficacy and safety of bevacizumab-combined chemotherapy with other treatments in patients with advanced/recurrent endometrial cancer.Results: Notably, 2 randomized-controlled and 5 single-arm trials of bevacizumab-combined chemotherapy or bevacizumab single-agent therapy for endometrial cancer were included. Meta-analysis indicated that bevacizumab-combined chemotherapy significantly increased the progression-free survival rate (hazard ratio=0.82, 95% confidence interval=0.70, 0.97) and overall survival rate (hazard ratio=0.83, 95% confidence interval=0.70, 0.98) compared with chemotherapy alone. The rates of overall, complete, and partial response to bevacizumab-combined chemotherapy were 76%, 22%, and 21%, respectively. The 6 and 12-month disease-free progression rates after bevacizumab-combined chemotherapy were 79% and 62%, respectively. Anemia (23%), leukopenia (46%), neutropenia (51%), hypertension (16%), and fatigue (24%) were the general adverse events after bevacizumab-combined chemotherapy.Conclusion: Bevacizumab-combined chemotherapy may have a higher efficacy in improving the overall and progression-free survival in patients with advanced/recurrent endometrial cancers compared with chemotherapy alone.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Marcus D, Savage A, Balog J, Kudo H, Abda J, Dina R, et al. P74 Endometrial cancer: Can the iKnife diagnose endometrial cancer? Int J Gynecol Cancer 2019;29:A100-A101. [Crossref]
- 2. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet 2016;387:1094-108. [Crossref]
- 3. Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C, et al. Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial Cancer: MITO END-2-A randomized phase II trial. Gynecol Oncol 2019;155:406-12. [Crossref]
- 4. Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Alvarez Secord A, et al. A Phase II Study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 2018;150:274-81. [Crossref]
- 5. Rose PG, Ali S, Moslemi-Kebria M, Simpkins F. Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma. Int J Gynecol Cancer 2017;27:452-58. [Crossref]
- 6. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001;80:181-8. [Crossref]
- 7. Dziobek K, Opławski M, Grabarek BO, Zmarzły N, Tomala B, Halski T, et al. Changes in the expression profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer. Curr Pharm Biotechnol 2019;20:955-63. [Crossref]
- 8. Miles D, Cameron D, Hilton M, Garcia J, O'Shaughnessy J. Overall survival in MERiDiAN, a double-blind placebo-controlled Randomised Phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. Eur J Cancer 2018;90:153-5. [Crossref]
- 9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;18:e123. [Crossref]
- 10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, DJG Phil, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. [Crossref]
- 11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument. Anz Journal of Surgery 2003;73:712-6. [Crossref]
- 12. Alvarez E, Brady W, Walker J, Rotmensch J, Zhou X, Kendrick J, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2012;125:S17. [Crossref]
- 13. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2011;29:2259-65. [Crossref]
- 14. Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N, Rose PG. A Phase II Trial of Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma (EMCA). Gynecol Oncol 2015;136:240-5. [Crossref]
- 15. Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007;27:3525-8.
- 16. Hua F, Tian Y. CCL4 Promotes the Cell Proliferation, invasion and migration of endometrial carcinoma by targeting the VEGF-A signal pathway. Int J Clin Exp Pathol 2017;10:11288-99.
- 17. Sopo M, Anttila M, Hämäläinen K, Kivelä A, Ylä-Herttuala S, Kosma VM, et al. Expression Profiles of VEGF-A, VEGF-D and VEGFR1 Are Higher in Distant Metastases Than in Matched Primary High Grade Epithelial Ovarian Cancer. BMC Cancer 2019;19:584. [Crossref]
- 18. Macedo F, Ladeira K, Longatto-Filho A, Martins SF. Gastric Cancer and Angiogenesis: Is VEGF A Useful Biomarker to Assess Progression and Remission? J Gastric Cancer 2017;17:1-10. [Crossref]
- 19. Frezzetti D, Gallo M, Maiello MR, D'Alessio A, Esposito C, Chicchinelli N, et al. VEGF as A Potential Target in Lung Cancer. Expert Opin Ther Targets 2017;21:959-66. [Crossref]
- 20. Mercurio AM. VEGF/Neuropilin Signaling in Cancer Stem Cells. Int J Mol Sci 2019;20:490. [Crossref]
- 21. Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, et al. Plasma VEGF Concentrations after Intravitreous Anti-VEGF Therapy for Diabetic Macular Edema. Ophthalmology 2018;125:1054-63. [Crossref]
- 22. Davies S, Dai D, Pickett G, Thiel KW, Korovkina VP, Leslieet KK. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. Oncol Rep 2011;25:855-62. [Crossref]
- 23. Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov 2004;3:995-6. [Crossref]
- 24. Meyerhardt JA, Li L, Sanoff HK, Carpenter 4th W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer. J Clin Oncol 2012;30:608-15. [Crossref]
- 25. Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009;66:999-1013. [Crossref]
- 26. von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. Oncologist 2018;23:654-e58. [Crossref]
- 27. Shah MK, Shah MA, Shah SD. Risk of Hypertension with Bevacizumab, An Antibody Against Vascular Endothelial Growth Factor A: A Systematic Review and Meta-Analysis. Int J Basic Clin Pharmacol 2019;8:2354. [Crossref]
- 28. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of Proteinuria and Hypertension with Bevacizumab, An Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis. Am J Kidney Dis 2007;49:186-93. [Crossref]
| APA | Chen H, LIANG M, Min J (2021). Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. , 7 - 12. 10.5152/balkanmedj.2021.20121 |
| Chicago | Chen Hui,LIANG MINGLIN,Min Jie Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. (2021): 7 - 12. 10.5152/balkanmedj.2021.20121 |
| MLA | Chen Hui,LIANG MINGLIN,Min Jie Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. , 2021, ss.7 - 12. 10.5152/balkanmedj.2021.20121 |
| AMA | Chen H,LIANG M,Min J Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. . 2021; 7 - 12. 10.5152/balkanmedj.2021.20121 |
| Vancouver | Chen H,LIANG M,Min J Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. . 2021; 7 - 12. 10.5152/balkanmedj.2021.20121 |
| IEEE | Chen H,LIANG M,Min J "Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis." , ss.7 - 12, 2021. 10.5152/balkanmedj.2021.20121 |
| ISNAD | Chen, Hui vd. "Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis". (2021), 7-12. https://doi.org/10.5152/balkanmedj.2021.20121 |
| APA | Chen H, LIANG M, Min J (2021). Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. Balkan Medical Journal, 38(1), 7 - 12. 10.5152/balkanmedj.2021.20121 |
| Chicago | Chen Hui,LIANG MINGLIN,Min Jie Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. Balkan Medical Journal 38, no.1 (2021): 7 - 12. 10.5152/balkanmedj.2021.20121 |
| MLA | Chen Hui,LIANG MINGLIN,Min Jie Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. Balkan Medical Journal, vol.38, no.1, 2021, ss.7 - 12. 10.5152/balkanmedj.2021.20121 |
| AMA | Chen H,LIANG M,Min J Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. Balkan Medical Journal. 2021; 38(1): 7 - 12. 10.5152/balkanmedj.2021.20121 |
| Vancouver | Chen H,LIANG M,Min J Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis. Balkan Medical Journal. 2021; 38(1): 7 - 12. 10.5152/balkanmedj.2021.20121 |
| IEEE | Chen H,LIANG M,Min J "Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis." Balkan Medical Journal, 38, ss.7 - 12, 2021. 10.5152/balkanmedj.2021.20121 |
| ISNAD | Chen, Hui vd. "Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis". Balkan Medical Journal 38/1 (2021), 7-12. https://doi.org/10.5152/balkanmedj.2021.20121 |
